Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLEX PFS vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and thereby interfering with DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and reduction of cytokine production.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Neoplastic diseases: gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole, acute lymphocytic leukemia, meningeal leukemia, breast cancer, head and neck cancer, advanced mycosis fungoides, lung cancer (especially squamous cell and small cell types), advanced non-Hodgkin's lymphomas.,Psoriasis (severe, recalcitrant, disabling, not adequately responsive to other therapy),Rheumatoid arthritis (active, severe, refractory to first-line therapy),Off-label uses: ectopic pregnancy, sarcoidosis, inflammatory bowel disease (Crohn's disease), vasculitis, systemic lupus erythematosus, dermatomyositis, juvenile idiopathic arthritis, graft-versus-host disease, multiple sclerosis, polymyositis, acute graft rejection prophylaxis
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
Methotrexate 30-40 mg/m2 IV once weekly or 7.5-15 mg PO once weekly as single dose or divided into 3 doses over 24 hours.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life: 6-12 hours in patients with normal renal function. With impaired renal function, half-life is prolonged (up to 24-48 hours). Low-dose methotrexate (e.g., for rheumatoid arthritis) has half-life 3-10 hours. High-dose methotrexate has a triphasic elimination: alpha phase (0.75 hours), beta phase (3.5 hours), and terminal gamma phase (10-20 hours).
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which are retained for prolonged periods. The primary metabolic pathway involves conversion to 7-hydroxymethotrexate by aldehyde oxidase. Renal excretion is the major route of elimination, with approximately 80-90% of the dose excreted unchanged in the urine within 24 hours. Enterohepatic recirculation occurs. Biliary excretion accounts for a minor fraction.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily renal excretion as unchanged drug; approximately 80-90% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<10%).
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 50% bound to serum albumin, primarily to albumin. Binding is saturable at high doses.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Volume of distribution: 0.4-0.8 L/kg (40-80 L/70 kg). Higher doses may increase Vd due to tissue binding. Distributes into third-space fluids, including pleural effusions and ascites.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral: 60-70% (dose-dependent, saturable absorption). IM: 76-100% relative to IV. IV: 100%.
Intravenous administration yields 100% bioavailability.
Cr Cl 30-60 m L/min: reduce dose by 30-50%; Cr Cl <30 m L/min: avoid use or use extreme caution with dose reduction >50%.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Juvenile idiopathic arthritis: 10-15 mg/m2 IV/IM once weekly; leukemia maintenance: 15-30 mg/m2 PO/IM once weekly.
Safety and effectiveness in pediatric patients have not been established.
Start at lower end of dosing range (e.g., 7.5-10 mg once weekly) due to reduced renal and hepatic function; monitor for myelosuppression and mucositis.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
WARNING: METHOTREXATE SHOULD BE USED ONLY BY PHYSICIANS EXPERIENCED IN ANTIMETABOLITE THERAPY. DEATHS HAVE BEEN REPORTED WITH THE USE OF METHOTREXATE IN THE TREATMENT OF MALIGNANCY, PSORIASIS, AND RHEUMATOID ARTHRITIS. PATIENTS SHOULD BE CLOSELY MONITORED FOR BONE MARROW SUPPRESSION, HEPATOTOXICITY, PULMONARY TOXICITY, AND RENAL TOXICITY. METHOTREXATE IS CONTRAINDICATED IN PREGNANCY AND LACTATION. DOSING FOR NON-NEOPLASTIC DISEASES (PSORIASIS AND RHEUMATOID ARTHRITIS) IS ONCE WEEKLY; DAILY DOSING HAS LED TO FATAL TOXICITY. ACCIDENTAL OVERDOSAGE HAS RESULTED IN FATALITIES.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Bone marrow suppression: leukopenia, thrombocytopenia, anemia, pancytopenia,Hepatotoxicity: acute hepatitis, hepatic fibrosis, cirrhosis (especially with chronic use),Pulmonary toxicity: pneumonitis, interstitial alveolitis, pulmonary fibrosis,Renal toxicity: nephropathy, renal failure (due to precipitation of methotrexate and its metabolites in the renal tubules),Gastrointestinal toxicity: ulcerative stomatitis, diarrhea, hemorrhagic enteritis,Infections: increased risk of opportunistic infections (e.g., Pneumocystis jirovecii pneumonia),Dermatologic reactions: photosensitivity, Stevens-Johnson syndrome,Neurologic effects: encephalopathy, seizures, headache,Monitoring: baseline and periodic complete blood counts, liver function tests, renal function tests, chest X-ray,Methotrexate elimination is impaired in patients with renal impairment, ascites, or pleural effusions, leading to increased toxicity,Concurrent use of NSAIDs may increase methotrexate toxicity
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Pregnancy and lactation (FDA Pregnancy Category X),Severe renal impairment (e GFR < 30 m L/min/1.73 m²),Severe hepatic impairment (cirrhosis, active hepatitis),Alcoholism or alcoholic liver disease,Pre-existing blood dyscrasias (e.g., bone marrow hypoplasia, severe anemia, leukopenia, thrombocytopenia),Active immunodeficiency syndromes (e.g., AIDS),Hypersensitivity to methotrexate or any component of the formulation,Concurrent treatment with live vaccines,Breastfeeding
None known.
Foods high in folate (e.g., dark leafy greens, beans, liver) may theoretically reduce methotrexate efficacy; however, patients are often given folic acid supplements to mitigate toxicity. Caffeine may interfere with methotrexate clearance; avoid excessive caffeine intake (e.g., >4 cups coffee/day). Grapefruit and grapefruit juice may increase methotrexate levels via CYP inhibition; avoid concurrent consumption. Alcohol consumption during methotrexate therapy significantly increases risk of hepatocellular injury and is contraindicated. Avoid folic acid-fortified foods (e.g., enriched cereals, breads) in large amounts unless supplementing under medical direction.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
FDA Pregnancy Category X. First trimester: severe teratogenic effects including neural tube defects, craniofacial anomalies, and limb defects. Second trimester: increased risk of fetal growth restriction, oligohydramnios, and fetal loss. Third trimester: neonatal myelosuppression, immunosuppression, and acute renal failure.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Contraindicated in breastfeeding. Methotrexate is excreted in human milk and can accumulate in neonatal tissues. M/P ratio not established but reported to be 0.08:1 in limited data.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
Not applicable; contraindicated in pregnancy. If inadvertent exposure occurs, immediate discontinuation is advised. Folinic acid rescue may be considered in first trimester exposure.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Methotrexate (FOLEX PFS) is a folate analog antimetabolite; always confirm dose and route as intrathecal use has high risk of neurotoxicity. Leucovorin rescue is mandatory after high-dose methotrexate (typically >500 mg/m²) to prevent severe myelosuppression and mucositis. Monitor renal function closely as methotrexate is primarily renally excreted; accumulation can cause acute kidney injury. Hydration and urine alkalinization (target urine p H >7) enhance excretion and reduce nephrotoxicity. Avoid concurrent use of NSAIDs and weak acids (e.g., aspirin, penicillin) as they decrease renal clearance. Intrathecal administration carries risk of chemical arachnoiditis, seizures, and leukoencephalopathy; assess for neurotoxicity symptoms after dosing. Methotrexate can cause pneumonitis; rule out infection if new respiratory symptoms develop.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take methotrexate exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol completely during treatment to reduce risk of hepatotoxicity.,Drink plenty of fluids (aim for 2-3 liters daily) to prevent kidney damage.,Notify your healthcare provider immediately if you develop mouth sores, fever, chills, sore throat, easy bruising/bleeding, shortness of breath, or yellowing of skin/eyes.,Women of childbearing potential must use effective contraception during treatment and for at least 3 months after last dose; methotrexate is teratogenic.,Do not take any over-the-counter pain relievers (especially NSAIDs like ibuprofen, naproxen) without clearance, as they increase toxicity risk.,Folic acid supplementation may be prescribed to reduce side effects; take it exactly as directed.,Avoid live vaccines while on treatment and for 3 months after discontinuation.,Limit sun exposure and use sunscreen as methotrexate may increase photosensitivity.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLEX PFS vs COLUMVI, answered by our medical review team.
FOLEX PFS is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and thereby interfering with DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and reduction of cytokine production.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLEX PFS and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLEX PFS is: Methotrexate 30-40 mg/m2 IV once weekly or 7.5-15 mg PO once weekly as single dose or divided into 3 doses over 24 hours.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLEX PFS and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLEX PFS is classified as Category C. FDA Pregnancy Category X. First trimester: severe teratogenic effects including neural tube defects, craniofacial anomalies, and limb defects. Second trimester: increased risk of f. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.